Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review

Abstract

Acquired hemophilia A (AHA), a rare but life-threatening disorder, most commonly occurs in older people and during pregnancy. During the coronavirus disease 2019 (COVID-19) vaccination campaign, an unexpected number of newly diagnosed AHA patients have been identified in clinical practice that were temporally related to COVID-19 vaccination. We present the result of a signal detection analysis aimed at exploring a possible association between COVID-19 immunization and occurrence of AHA. A disproportionality analysis on the World Health Organization (WHO) database was performed to investigate the presence of a signal of risk for AHA associated with COVID-19 vaccines. Reports of AHA associated with any COVID-19 vaccine included in the WHO database were then integrated with those available on the Food and Drug Administration Vaccine Adverse Events Reporting System and those published in the medical literature. The WHO database included 146 reports of AHA. The information component (IC) was significant for the association of AHA with all COVID-19 vaccines (IC025: 1.1) and with the vaccine product BNT162b2 (IC025: 1.6). After duplicate exclusion, 96 unique cases of AHA following COVID-19 vaccines have been reviewed. Median time to diagnosis was 18 days and 40% of cases documented the occurrence after the second dose. Overall, in 57% of the investigated cases, a preexisting condition predisposing to AHA was excluded. About 22% of cases occurred in subjects with age ≤65 years and there was no case associated with pregnancy. Mortality was 11%. Although we cannot exclude that the unexpected frequency of AHA diagnosis can be explained by a detection bias, the signal for COVID-19 vaccine-related AHA is robust and deserves further investigations.

Keywords

acquired haemophilia A autoimmunity - COVID-19 - mRNA vaccines - BNT162b2 - mRNA-1273

Author Contributions

M.F., M.T., and D.F. conceived and developed the presented idea. M.F. and D.F. wrote the first draft. U.M. curated [Table 1]. E.C., G.V., and M.B. curated [Fig. 1], [Tables 2]–[4], and supplementary data. M.T. wrote the paper with input from all the authors.

Publikationsverlauf

Artikel online veröffentlicht:
02. September 2022

• References

• 1 Franchini M, Vaglio S, Marano G. et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017; 22 (09) 514-520
• 2 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (05) 433-446
• 3 Franchini M, Marano G, Cruciani M. et al. Advances in managing rare acquired bleeding disorders. Expert Rev Hematol 2020; 13 (06) 599-606
• 4 Collins PW, Hirsch S, Baglin TP. et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (05) 1870-1877
• 5 Knoebl P, Marco P, Baudo F. et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (04) 622-631
• 6 Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81 (10) 768-773
• 7 Tengborn L, Baudo F, Huth-Kühne A. et al; EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119 (12) 1529-1537
• 8 Kruse-Jarres R, Kempton CL, Baudo F. et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 2017; 92 (07) 695-705
• 9 Franchini M, Capra F, Nicolini N. et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit 2007; 13 (04) RA55-RA61
• 10 Kessler CM, Ma AD, Al-Mondhiry HAB, Gut RZ, Cooper DL. Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry. Blood Coagul Fibrinolysis 2016; 27 (07) 761-769
• 11 Sun B, Xue F, Feng Y. et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. Br J Haematol 2019; 187 (05) 653-665
• 12 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125 (07) 1091-1097
• 13 Ferri GM, Vaccaro F, Caccavo D, Imperato G, Bonomo L. Development of factor VIII:C inhibitors following vaccination. Acta Haematol 1996; 96 (02) 110-111
• 14 Moulis G, Pugnet G, Bagheri H. et al. Acquired factor VIII haemophilia following influenza vaccination. Eur J Clin Pharmacol 2010; 66 (10) 1069-1070
• 15 Pirrotta MT, Bernardeschi P, Fiorentini G. A case of acquired haemophilia following H1N1 vaccination. Haemophilia 2011; 17 (05) 815-815
• 16 Al Hennawi H, Al Masri MK, Bakir M. et al. Acquired hemophilia A post-COVID-19 vaccination: a case report and review. Cureus 2022; 14 (02) e21909
• 17 Radwi M, Farsi S. A case report of acquired hemophilia following COVID-19 vaccine. J Thromb Haemost 2021; 19 (06) 1515-1518
• 18 Lemoine C, Giacobbe AG, Bonifacino E, Karapetyan L, Seaman C. A case of acquired haemophilia A in a 70-year-old post COVID-19 vaccine. Haemophilia 2022; 28 (01) e15-e17
• 19 Farley S, Ousley R, Van Wagoner N, Bril F. Autoimmunity after coronavirus disease 2019 (COVID-19) vaccine: a case of acquired hemophilia A. Thromb Haemost 2021; 121 (12) 1674-1676
• 20 Portuguese AJ, Sunga C, Kruse-Jarres R, Gernsheimer T, Abkowitz J. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv 2021; 5 (13) 2794-2798
• 21 Leone MC, Canovi S, Pilia A. et al. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine. Thromb Res 2022; 211: 60-62
• 22 Cittone MG, Battegay R, Condoluci A. et al. The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination. J Thromb Haemost 2021; 19 (09) 2360-2362
• 23 Murali A, Wong P, Gilbar PJ, Mangos HM. Acquired hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab. J Oncol Pharm Pract 2022; 28 (06) 1450-1453
• 24 Gonzalez R, Gutierrez-Nunez J, Ferrer VF, Torres G, Cardin NA. “Dark skin” Acquired Hemophilia A After Pfizer-Biontech COVID-19 Vaccine. Chest 2021; 160 (04) A1384
• 25 Soliman DS, Al Battah A, Al Faridi D, Ibrahim F. Acquired hemophilia A developed post COVID-19 vaccine: an extremely rare complication. J Med Cases 2022; 13 (01) 1-4
• 26 Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 2020; 43 (05) 479-487
• 27 Bate A, Lindquist M, Edwards IR. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54 (04) 315-321
• 28 Vaccine Adverse Event Reporting System (VAERS). World Health Organization; 2019 https://vaers.hhs.gov/data.html
• 29 European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Accessed June 29, 2022 at: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood#::~text=EMA%20confirms%20overall%20benefit%2Drisk,COVID%2D19%20Vaccine%20AstraZeneca)
• 30 Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 2021; 107 (02) 173-180
• 31 COVID-19 Vaccine Janssen. . EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. European Medicines Agency; 2021. Accessed June 29, 2022 at: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood#:~:text=At%20its%20meeting%20of%2020,side%20effects%20of%20the%20vaccine
• 32 Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength. Hosp Pharm 2021; 56 (03) 152-158
• 33 Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10) 891-898
• 34 Hirsiger JR, Martinez M, Tsakiris DA. et al. Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines. J Thromb Haemost 2022; 20 (04) 1015-1018
• 35 Meunier S, Menier C, Marcon E, Lacroix-Desmazes S, Maillère B. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv 2017; 1 (21) 1842-1847
• 36 Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 1992; 89 (09) 3795-3799
• 37 Coppola A, Franchini M, Tripodi A. et al; ad hoc Working Group (Appendix 1). Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. Blood Transfus 2022; 20 (03) 245-262
• 38 Hauben M, Reich L, DeMicco J, Kim K. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf 2007; 30 (06) 551-554
• 39 Hauben M, Zou C, Bright S, Hung E. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis. Pharmacoepidemiol Drug Saf 2021; 30 (08) 1140-1141
• 40 Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 2007; 14 (03) 305-328